更新版 1-AnaptysBio公司在中期试验失败后放弃湿疹药物开发

Reuters
11 Dec 2024

((自动化翻译由路透提供,请见免责声明 )) (第2段增加股票,全文增加细节)

路透12月11日 - AnaptysBio 周三表示,由于未能达到中期试验的主要和次要目标,该公司将终止湿疹药物的开发。

该公司股票在盘前交易中停牌。

该药物 ANB032 没有达到主要目标,即湿疹严重程度指数比基线至少改善 75% 的患者比例。

公司首席执行官丹尼尔-法加(Daniel Faga)在一份声明中说,公司将专注于自身免疫产品组合的其他部分,其中包括治疗类风湿性关节炎和一种炎症性肠病的药物。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10